TY - JOUR
T1 - Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma
AU - Blaiss, Michael S.
AU - Castro, Mario
AU - Chipps, Bradley E.
AU - Zitt, Myron
AU - Panettieri, Reynold A.
AU - Foggs, Michael B.
N1 - Funding Information:
Funding Sources: The roundtable meeting and medical writing and editorial assistance were supported by an independent education grant from Boston Scientific. The supporter had no role in the development or approval of this report.
Publisher Copyright:
© 2017 American College of Allergy, Asthma & Immunology
PY - 2017/12
Y1 - 2017/12
N2 - Background Severe asthma poses significant disease-related and economic burdens in the United States. Challenges in practice include how to define “severe asthma” for a given patient, knowing which are the right tests to perform and when, and having a better understanding of a patient's asthma phenotype. Furthermore, current guidelines do not address a clear, practical approach to treatment that is based on a patient's asthma phenotype. Objective To develop a consensus on the definition of severe asthma, the role of biomarkers and phenotyping severe asthma, and the use of newer biologic therapies and bronchial thermoplasty to help guide practicing clinicians. Methods A roundtable meeting was convened with a panel of severe asthma experts to discuss areas in practice that are not adequately addressed by current guidelines, specifically phenotype-guided treatment. Results We describe a consensus on the definition of severe asthma, asthma phenotyping with the use of available biomarkers, and guiding principles for newer biologic therapies and bronchial thermoplasty. Conclusion To optimize therapy and improve outcomes such as daily symptoms, quality of life, exacerbations, and hospitalizations, a clear picture of a patient's asthma phenotype is needed to guide therapy. Determining asthma phenotypes is the foundation of precision medicine for this persistent, often difficult-to-treat disease.
AB - Background Severe asthma poses significant disease-related and economic burdens in the United States. Challenges in practice include how to define “severe asthma” for a given patient, knowing which are the right tests to perform and when, and having a better understanding of a patient's asthma phenotype. Furthermore, current guidelines do not address a clear, practical approach to treatment that is based on a patient's asthma phenotype. Objective To develop a consensus on the definition of severe asthma, the role of biomarkers and phenotyping severe asthma, and the use of newer biologic therapies and bronchial thermoplasty to help guide practicing clinicians. Methods A roundtable meeting was convened with a panel of severe asthma experts to discuss areas in practice that are not adequately addressed by current guidelines, specifically phenotype-guided treatment. Results We describe a consensus on the definition of severe asthma, asthma phenotyping with the use of available biomarkers, and guiding principles for newer biologic therapies and bronchial thermoplasty. Conclusion To optimize therapy and improve outcomes such as daily symptoms, quality of life, exacerbations, and hospitalizations, a clear picture of a patient's asthma phenotype is needed to guide therapy. Determining asthma phenotypes is the foundation of precision medicine for this persistent, often difficult-to-treat disease.
UR - http://www.scopus.com/inward/record.url?scp=85034956727&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2017.09.058
DO - 10.1016/j.anai.2017.09.058
M3 - Article
C2 - 29103801
AN - SCOPUS:85034956727
SN - 1081-1206
VL - 119
SP - 533
EP - 540
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 6
ER -